ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

May 9, 2022

The Centers for Medicare & Medicaid Services (CMS) released the Contract Year 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs final rule. The rule finalizes the administration’s efforts to improve consumer protections, reduce disparities, and improve equity in the MA and Medicare Part D programs in 2023 and beyond.

May 5, 2022

The Food and Drug Administration (FDA) recently announced two proposed rules. One proposal would ban menthol as a characterizing flavor in cigarettes, and the other would ban all characterizing flavors (other than tobacco) in cigars.

May 5, 2022

On May 4, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. 

May 3, 2022

On May 3, ASCO's CancerLinQ® and Atropos Health announced a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.

May 3, 2022

Today the American Society of Clinical Oncology (ASCO) announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, four-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 medical schools will lead approximately 50 students in a hybrid curriculum developed by members of ASCO’s OSI Advisory Group and each participating medical school’s internship leaders.

April 29, 2022

The Centers for Medicare & Medicaid Services released the Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters final rule. The rule finalizes regulatory changes in the individual and small group health insurance markets and establishes parameters and requirements issuers need to design plans and set rates for the 2023 plan year. The rule also aims to improve enrollment policies for qualified health plans offered on the federal Marketplace to ensure consumer access to quality and affordable coverage and to advance health equity.

April 26, 2022

The Centers for Medicare & Medicaid Services (CMS) recognizes the impact that the COVID-19 pandemic public health emergency (PHE) continued to have on clinicians and the services they provided during the Quality Payment Program’s 2021 performance period. As such, CMS is reweighting Merit-based Incentive Payment System (MIPS) cost performance category from 20% to 0% for the 2021 performance period for both groups and individuals.

April 25, 2022

A new article published in the American Cancer Society’s Cancer journal shares results from a national, online patient survey conducted by American Society of Clinical Oncology (ASCO), which assessed practice patterns related to weight, diet, and exercise as part of cancer care.

April 21, 2022

The Association for Clinical Oncology (ASCO) responded to a Centers for Medicare & Medicaid Services-issued Request for Information on the barriers that people face when trying to enroll and maintain health care coverage in Medicaid and the Children’s Health Insurance Program. ASCO is committed to advocating for coverage and reimbursement, access and quality, and cancer research and prevention policies that promote high-quality, equitable cancer care throughout the health care system.

April 19, 2022

The Centers for Medicare & Medicaid Services issued the fiscal year 2023 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long‑Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. In addition to updating Medicare payment rates and policies for inpatient hospitals in FY 2023, the proposed rule aims to measure health care quality disparities, improve the quality of maternity care, and obtain stakeholder feedback to advance health equity.

April 12, 2022

From April 4-8, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2022 ASCO Week of Action, which was held in conjunction with the Association’s annual Advocacy Summit. During the Week of Action, advocates from across the country sent a record 920 letters to Members of Congress through ASCO’s ACT Network urging them to take action on important policies to improve access to high-quality, equitable care for people with cancer.

April 12, 2022

The American Society of Clinical Oncology (ASCO) today announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community.

April 11, 2022

The Centers for Medicare & Medicaid Services issued a proposed rule in the Federal Register that, if finalized, would delay the start date of the agency’s Radiation Oncology Model from January 1, 2023, to “a date to be determined through future rulemaking.”

April 7, 2022

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research. 

April 7, 2022

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.

Pages